Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Background: Patients treated with daily growth hormone (hGH; somatropin) therapy have long requested the option of a treatment requiring fewer injections. Once-weekly TransCon hGH is an investigational long-acting prodrug in development for the treatment of growth hormone deficiency (GHD) designed to fulfill this unmet need. TransCon hGH consists of 3 components: unmodified hGH, an inert carrier that protects it, and a linker that temporarily binds the two.
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Background: With growth hormone (GH) receptors present on virtually all cells, GH replacement therapy should aim for the same exposure and tissue distribution as endogenous GH and current daily GH therapies.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
